Campbell Alliance Announces Windhover Top 10 Oncology Products for 2011

November 29, 2011


Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced the assets chosen for the 2011 Top 10 Most Licensable Oncology Products to Watch. Selected projects will be discussed in more detail at the upcoming Windhover Therapeutic Area Partnerships conference (http://www.tapartnerships.com) in Boston, November 30 through December 2. 

Narrowed from a field of over 1,700 oncology assets using a strict set of judging criteria, the selected projects represent what are considered the most attractive licensable oncology opportunities the industry has to offer. Specifically, the selection team focused on what are considered “hot areas” in oncology:  those with transformational, nascent therapies where the potential for differentiation is high. Conjugated antibody, cancer metabolism, and immuno-oncology technologies dominated the list this year.

“Our approach this year was to look at differentiated molecular pathways and technologies,” said Jonathon Fendelman, Senior Practice Executive at Campbell Alliance.   “While these targeted approaches tend to address smaller patient populations initially, a great deal of potential exists for add-on indications, which makes them attractive licensing opportunities. Further, strong differentiation raises the likelihood of reimbursement post-approval, which is key in an increasingly payer-driven market. ”

2011 Top 10 Most Licensable Oncology Projects to Watch
Company
Asset/Compound
Location
Website
Advaxis
ADXS-HPV
US/New Jersey
www.advaxis.com
Altor
ALT-801
US/Florida
www.altorbioscience.com
Aveo
Ficlatuzumab
US/Massachusetts
www.aveopharma.com
Biotest AG
BT-062
Germany
www.biotest.com
Celldex
CDX-011
US/Massachusetts
www.celldextherapeutics.com
Endocyte
EC145
US/Indiana
www.endocyte.com
ImmunoCellular Therapeutics
ICT-107
US/California
www.imuc.com
Immune System Therapeutics 
MDX 1097
Australia
www.istl.com.au
Neogenix Oncology
Ensituximab/NPC-1C
US/New York
www.neogenix.com
Ruga
STF-31
US/California
www.rugacorp.com


Campbell Alliance has served as advisor for the oncology track of the Therapeutic Area Partnerships event since 2007. More information on Campbell Alliance’s Top 10 Oncology Projects can be found at http://www.campbellalliance.com/OncTop10


Windhover originally announced the full list of companies selected as part of the Therapeutic Area Partnerships conference on November 1. The list included assets from each of several therapeutic areas:  cardiovascular/metabolic, oncology, neuroscience, infectious diseases, and inflammatory/autoimmune, plus a "hot space" category, including ophthalmology, orphan diseases, and women's health.


About Campbell Alliance

Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry.  The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales.  From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.  


inVentiv Health Consulting offers world class healthcare consulting services.

Media Contact:

Stephanie Koenig
stephanie.koenig@inventivhealth.com